The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer | Journal of Experimental & Clinical Cancer Research | Full Text

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer | Journal of Experimental & Clinical Cancer Research | Full Text

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Small cell lung cancer (SCLC) is a deadly neuroendocrine tumor with limited therapeutic options. Recent data suggest that histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K) pathway play ...

Authors:Liying Ma, Xing Bian and Wenchu Lin

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:219

Content type:Research

 

Published on: 17 October 2020

• ViewFull Text
 
• ViewPDF